HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Walters, M. C. Search for Related Content PubMed PubMed Citation Articles by Walters, M. C. Social Bookmarking                   What's this?

Stem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy

Correspondence: Mark C. Walters, MD, Children’s Hospital and Research Center– Oakland, 747 52nd Street, Oakland CA 94609-1809; Phone (510) 428-3374, Fax (510) 601-3916, mwalters{at}mail.cho.org

Abstract

HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) has a strong track record of efficacy and there is growing appreciation that its benefits exceed its risks in selected individuals. In contrast, the clinical utility of replacement gene therapy for sickle cell disease remains unproven. Its challenge is to ensure viral transduction into hematopoietic stem cells (HSCs) and to generate safe, stable, erythroid-specific replacement gene expression at a level that is sufficient to have a clinical effect. The clinical necessity for fulfilling all these criteria may make this genetic disorder among the most complex to treat successfully by gene therapy. But the experience of HCT for SCD has proven that eliminating the ß^S-globin gene is curative when the transfer is stable. Thus replacement gene therapy for sickle cell disease remains a subject of intense interest and investigation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?